FindTrial
Sign In

growth factor antagonist therapy

PROCEDURE7 trials

Sponsors

University of Pittsburgh, National Cancer Institute (NCI), Barbara Ann Karmanos Cancer Institute, SWOG Cancer Research Network, The Cleveland Clinic

Conditions

Adenocarcinoma of the PancreasGastrointestinal Carcinoid TumorHead and Neck CancerHigh-grade Squamous Intraepithelial LesionIslet Cell CarcinomaNon-melanomatous Skin CancerRecurrent Pancreatic CancerRefractory Plasma Cell Neoplasm

Phase 1

Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors
WithdrawnNCT00052403
Barbara Ann Karmanos Cancer InstituteUnspecified Adult Solid Tumor, Protocol Specific
Start: 2002-02-28Updated: 2014-01-16
Gene Therapy in Treating Patients With Advanced Head and Neck Cancer
CompletedNCT00009841
University of PittsburghHead and Neck Cancer
Start: 1999-03-31End: 2002-03-31Updated: 2016-02-12

Phase 2

Celecoxib in Preventing Skin Cancer
WithdrawnNCT00025051
National Cancer Institute (NCI)Non-melanomatous Skin Cancer
Updated: 2013-03-22
S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix
WithdrawnNCT00072540
SWOG Cancer Research NetworkHigh-grade Squamous Intraepithelial Lesion, Stage 0 Cervical Cancer
Updated: 2013-11-08
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma
WithdrawnNCT00112879
The Cleveland ClinicRefractory Plasma Cell Neoplasm, Stage III Multiple Myeloma, Stage II Multiple Myeloma +1
Updated: 2013-07-10
Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
WithdrawnNCT00227773
Eastern Cooperative Oncology GroupGastrointestinal Carcinoid Tumor, Islet Cell Carcinoma
Updated: 2015-10-08
Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer
WithdrawnNCT00253526
National Cancer Institute (NCI)Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer +2
Updated: 2015-04-28